Awardee OrganizationBOSTON UNIVERSITY MEDICAL CAMPUS
Description
Abstract Text
Apoptosis or programmed cell death (PCD) is a general mechanism of cell
suicide that has been implicated in tolerization of B lymphocytes. For
example, treatment of the murine early B lymphoma WEHI 231 line, a model
for study of B cell tolerance, with an antiserum against its expressed
surface IgM, such as goat anti-mouse Ig (GaMIg) or anti-mu antisera,
inhibits its proliferation via apoptosis. Oligosomal degradation of DNA
is detectable by 12 hours post-GaMIg treatment. Recent evidence has
demonstrated that the expression of the nuclear proto-oncogene c-myc is
necessary for PCD, promoting apoptosis in a dose-dependent fashion. Here
the role of c-myc in apoptosis will be explored using the WEHI 231 line
as model system. The expression of c-myc in WEHI 231 cells and the
effects of apoptosis have been extensively characterized by ongoing work
from the PI's and other laboratories. Treatment of WEHI 231 cells with
GaMIg results in an initial increase in expression of c-myc RNA of 5- to
10-fold by 1-2 hours, which is followed by a dramatic decline by 4-6
hours post-treatment. The synthesis of c-myc protein parallels the early
changes in RNA levels; furthermore, the protein is transiently
hyperphosphorylated at 1 hour. By 24 hours, mRNA and protein levels are
well below those observed in control cells. A major site of control of
these changes in c-myc RNA expression is mediated at the transcription
level. The increase in c-myc expression appears to be critical for
apoptosis. For example, the PI's laboratory has recently shown that
treatment with an anti-delta antiserum of a WEHI 231 line stably
transfected with a delta heavy chain (WEHI 231-delta), which fails to
induce apoptosis, failed to induce c-myc protein levels, in contrast to
treatment with anti-mu serum. Thus the aims of this proposal are to 1)
measure the effects of anti-Ig treatment on c-myc protein expression, and
2) characterize the transcription factors mediating the changes in c-myc
RNA levels; particular emphasis, will be placed on the nuclear factor
NF-KB, which the PI's laboratory has demonstrated plays a major role in
regulation of c-myc transcription. Specifically, post-translational
modifications and association of c-myc with other cellular proteins will
be examined. The biochemical nature and functional effects of changes in
expression of NF-KB, noted during apoptosis, will be measured. Results
will be correlated with apoptosis through use of the WEHI 231-delta line.
These studies should provide important insights into the control of
apoptosis in lymphocytes, the development of B cell tolerance and the
role of the c-myc oncogene in these processes.
No Sub Projects information available for 2R01CA036355-09A2
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 2R01CA036355-09A2
Patents
No Patents information available for 2R01CA036355-09A2
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 2R01CA036355-09A2
Clinical Studies
No Clinical Studies information available for 2R01CA036355-09A2
News and More
Related News Releases
No news release information available for 2R01CA036355-09A2
History
No Historical information available for 2R01CA036355-09A2
Similar Projects
No Similar Projects information available for 2R01CA036355-09A2